Wilmington, Delaware, November 2025 AstraZeneca has announced that Koselugo (selumetinib) has received expanded FDA approval in the United States for treating children with neurofibromatosis type 1 (NF1) presenting with symptomatic, inoperable plexiform neurofibromas. This landmark approval strengthens the therapy’s global positioning and reinforces AstraZeneca’s commitment to precision medicine for rare and debilitating diseases.
Science Significance
NF1 arises from mutations in the NF1 gene, leading to dysregulated RAS pathway signalling and uncontrolled tumour growth. Selumetinib inhibits MEK — a critical downstream activator of the RAS/MAPK pathway — thereby blocking tumour proliferation at the molecular level. Clinical studies show objective response rates exceeding 60%, including durable tumour shrinkage and improved motor function. These outcomes validate MEK inhibition as a scientifically robust therapeutic strategy and mark a turning point in genotype-driven paediatric oncology. Additionally, Koselugo’s formulation allows predictable pharmacokinetics in children and a manageable safety profile, making it a scientifically suitable long-term therapy for this chronic condition.
Regulatory Significance
The FDA’s decision is the culmination of a rigorous evaluation involving phase 2 clinical data, real-world evidence, and post-marketing surveillance outcomes. Given NF1’s classification as a rare and debilitating disease, Koselugo benefits from Orphan Drug designation, which provides enhanced regulatory incentives, including extended exclusivity and streamlined guidance support. This approval also positions Koselugo for broader global regulatory submissions, including in Asia-Pacific and emerging markets, aligning with international frameworks like EMA’s PRIME and PMDA’s Sakigake initiatives. The decision sets a precedent for approving targeted genetic therapies based on clinically meaningful non-traditional endpoints such as functional gains, pain reduction, and improved movement.
Advertisement
Business Significance
For AstraZeneca, this latest approval represents an expansion of its rare-disease franchise and reinforces its leadership in paediatric precision therapy markets. Koselugo’s commercial potential is strengthened by increasing NF1 awareness, improved diagnostic practices, and deeper engagement with paediatric oncology networks. The market for rare paediatric tumour therapies continues to grow rapidly, supported by payer acceptance for high-value targeted treatments. With this approval, AstraZeneca positions itself for strategic collaborations, global market penetration, and strong long-term revenue growth within a niche but underserved therapeutic segment.
Patients Significance
Children diagnosed with NF1 often endure chronic pain, organ dysfunction, and impaired mobility. Many face lifelong disability, surgery, or disfigurement. Koselugo offers one of the first true disease-modifying interventions, reducing tumour volume, decreasing pain, improving function, and enabling greater independence. Parents and caregivers gain a non-invasive therapeutic option that reduces surgical reliance and delays progression. The therapy’s oral administration further enhances adherence, making ongoing treatment more accessible for families.
Policy Significance
Koselugo’s approval aligns with policies aimed at accelerating treatment options for rare diseases. It reflects the importance of frameworks such as the Orphan Drug Act, paediatric exclusivity, and federal initiatives promoting genomic medicine. The decision also reinforces the call for improved funding of rare-disease research and underscores the value of cross-sector collaboration among researchers, clinicians, regulators, and patient advocacy groups
AstraZeneca’s expanded US approval for Koselugo marks a breakthrough in paediatric tumour therapy. With strong scientific foundations, regulatory endorsement, and meaningful patient benefits, the therapy stands as a shining example of how targeted innovation can reshape the treatment landscape for rare genetic diseases. Koselugo represents not only scientific progress but also renewed hope for children and families navigating the challenges of NF1.
Source: AstraZeneca press release
